Since, to our knowledge, no prior studies have investigated tumor stroma-dependent global gene expression changes in TKI-treated EML4-ALK-positive NSCLC, the aim of our study was to explore tumor stroma-related processes leading to nongenetic resistance in this tumor type. This evidence concerns the gene ALK and non-small cell lung carcinoma.